These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18097161)

  • 1. Hsp104: a weapon to combat diverse neurodegenerative disorders.
    Shorter J
    Neurosignals; 2008; 16(1):63-74. PubMed ID: 18097161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saccharomyces cerevisiae Hsp104 enhances the chaperone capacity of human cells and inhibits heat stress-induced proapoptotic signaling.
    Mosser DD; Ho S; Glover JR
    Biochemistry; 2004 Jun; 43(25):8107-15. PubMed ID: 15209506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of the molecular chaperone Hsp104 from yeast.
    Grimminger-Marquardt V; Lashuel HA
    Biopolymers; 2010 Mar; 93(3):252-76. PubMed ID: 19768774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neurodegenerative amyloidoses: the yeast model].
    Vishnevskaia AB; Kushnirov VV; Ter-Avanesian MD
    Mol Biol (Mosk); 2007; 41(2):346-54. PubMed ID: 17514901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular chaperone Hsp104--a molecular machine for protein disaggregation.
    Bösl B; Grimminger V; Walter S
    J Struct Biol; 2006 Oct; 156(1):139-48. PubMed ID: 16563798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering enhanced protein disaggregases for neurodegenerative disease.
    Jackrel ME; Shorter J
    Prion; 2015; 9(2):90-109. PubMed ID: 25738979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applying Hsp104 to protein-misfolding disorders.
    Vashist S; Cushman M; Shorter J
    Biochem Cell Biol; 2010 Feb; 88(1):1-13. PubMed ID: 20130674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation.
    Tessarz P; Mogk A; Bukau B
    Mol Microbiol; 2008 Apr; 68(1):87-97. PubMed ID: 18312264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson's disease.
    Gade VR; Kardani J; Roy I
    Int J Biochem Cell Biol; 2014 Oct; 55():87-92. PubMed ID: 25161148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid peptides and proteins in review.
    Harrison RS; Sharpe PC; Singh Y; Fairlie DP
    Rev Physiol Biochem Pharmacol; 2007; 159():1-77. PubMed ID: 17846922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering therapeutic protein disaggregases.
    Shorter J
    Mol Biol Cell; 2016 May; 27(10):1556-60. PubMed ID: 27255695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparate Mutations Confer Therapeutic Gain of Hsp104 Function.
    Jackrel ME; Yee K; Tariq A; Chen AI; Shorter J
    ACS Chem Biol; 2015 Dec; 10(12):2672-9. PubMed ID: 26441009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification of hsp104, a protein disaggregase.
    Sweeny EA; DeSantis ME; Shorter J
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21989490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanidine hydrochloride inhibits Hsp104 activity in vivo: a possible explanation for its effect in curing yeast prions.
    Jung G; Masison DC
    Curr Microbiol; 2001 Jul; 43(1):7-10. PubMed ID: 11375656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils.
    Arimon M; Grimminger V; Sanz F; Lashuel HA
    J Mol Biol; 2008 Dec; 384(5):1157-73. PubMed ID: 18851977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins.
    Jackrel ME; Shorter J
    Dis Model Mech; 2014 Oct; 7(10):1175-84. PubMed ID: 25062688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
    Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
    Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.
    Lo Bianco C; Shorter J; Régulier E; Lashuel H; Iwatsubo T; Lindquist S; Aebischer P
    J Clin Invest; 2008 Sep; 118(9):3087-97. PubMed ID: 18704197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of disease II: cellular protein quality control.
    Outeiro TF; Tetzlaff J
    Semin Pediatr Neurol; 2007 Mar; 14(1):15-25. PubMed ID: 17331880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.